OptimizeRx (NASDAQ:OPRX) Price Target Raised to $24.00

OptimizeRx (NASDAQ:OPRX) had its price objective increased by Citizens Jmp from $23.00 to $24.00 in a report issued on Friday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OptimizeRx in a research note on Wednesday, October 8th. JMP Securities boosted their target price on shares of OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, UBS Group set a $23.00 price objective on OptimizeRx in a research report on Friday, October 10th. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.45.

OptimizeRx Price Performance

Shares of OptimizeRx stock traded up $0.86 during trading on Friday, reaching $16.51. 485,272 shares of the stock traded hands, compared to its average volume of 372,465. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $22.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The business has a fifty day simple moving average of $18.87 and a two-hundred day simple moving average of $15.20. The company has a market capitalization of $306.51 million, a price-to-earnings ratio of -30.57 and a beta of 1.24.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%.The company had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that OptimizeRx will post -0.33 EPS for the current year.

Insider Buying and Selling at OptimizeRx

In related news, Director Patrick D. Spangler sold 11,120 shares of OptimizeRx stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the completion of the sale, the director owned 44,215 shares in the company, valued at $773,320.35. This trade represents a 20.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the completion of the transaction, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OPRX. Nisa Investment Advisors LLC raised its position in OptimizeRx by 600.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the second quarter valued at $44,000. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after acquiring an additional 2,215 shares in the last quarter. USA Financial Formulas purchased a new stake in OptimizeRx in the third quarter worth about $131,000. Finally, Wesbanco Bank Inc. purchased a new stake in OptimizeRx in the third quarter worth about $205,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.